Back to Basics? Physician Awareness and Nucleic Acid-Based Therapies

February 1, 2020
Meghan Oates-Zalesky
Applied Clinical Trials
Volume 29, Issue 2

Survey data finds that physicians aren’t very familiar with the intricacies of nucleic acid-based therapies.

Despite the buzz, physicians have limited familiarity and understanding with the burgeoning category of nucleic acid-based therapies. New data sourced in September 2019 by InCrowd, a real-time market insights technology firm, provides a baseline on physicians’ current knowledge regarding the different types of therapies, their mechanisms of action, and their perceived current impact and future promise. Based on responses, the market shows significant knowledge gaps.

Only 56% of screened respondents report being at least somewhat familiar with the seven leading nucleic acid-based therapies today-RNAi, siRNA, ASO, mRNA, AAV, CRISPR, and TALENs. Only 28% of physicians surveyed considered themselves familiar or very familiar with these therapies, and only 7% reported high familiarity.

Oncologists have the highest familiarity of the specialists surveyed, at 52% (compared to 20% of PCPs and 15% of pediatricians). Physicians in academic settings noted greater familiarity (34%) than physicians in non-academic community practices (24%). 

The terms mRNA and CRISPR are the most familiar, at 92% and 64%, respectively, for familiarity. Less than half of respondents were familiar with AAV (44%), siRNA (39%), RNAi (38%), and ASO (36%)-and less than a fifth (19%) with TALENS. Again, oncologists had the highest familiarity across terms compared to PCPs and pediatricians.

Academic-based physicians reported higher levels of awareness on many terms. For example, 70% of academic practice-based respondents are familiar with CRISPR versus 58% in non-academic settings.

There was a lack of knowledge around which among the list was a gene therapy. CRISPR, TALENS, and AAV are most commonly considered “gene therapies” by respondents, at 92%, 72%, and 67% respectively. About half associate the term with other therapies including RNAi (54%), siRNA (53%), ASO (51%), and mRNA (48%).

CRISPR also led the ranking for promising treatments, at 27% among all respondents, and 44% among oncologists. mRNA ranked second, at 8% of respondents. Practice setting-academic vs. community-based-did not impact results.

Beyond basic uses

Understanding basic uses for nucleic acid-based therapies-like the use of CRISPR for permanent DNA edits, and the use of mRNA and AAV for the creation of vaccine vectors-varied between one-third to two-thirds of respondents. Significant confusion existed on:

  • 65% of respondents in academic practices, and 75% of oncologists, correctly identified that CRISPR Involves intentional and permanent changes at the DNA level.

  • 36% correctly said that CRISPR may cause unintended permanent changes at the DNA level, yet 35% said no other among the listed gene-based therapies did, when TALENS and AAV also risk potential unintended changes.

  • Only 30% identified that AAV and mRNA can be used to make vaccines. 32% were unsure.

  • A striking 83% of respondents are unaware of any approved nucleic acid-based therapies that are on the market-despite FDA approved Alynylam’s Onpattro and Novartis’ Zolgensma.

The findings suggest biotechs and pharma firms face an opportunity for physician outreach and education on gene-based therapy fundamentals, as well as initiatives that build awareness of approved therapies and progress of others through the pipeline.

The survey included a total of 250 clinicians, including PCPs (48%), oncologists (32%), and pediatricians (20%), with a near equal split between those academically associated (47%) and non-associated (53%) practices. Each respondent needed to have at least a limited familiarity with RNA- or DNA-based therapeutic methods at a minimum to complete the survey.

 

Meghan Oates-Zalesky, Senior VP of Marketing, InCrowd

download issueDownload Issue : Applied Clinical Trials-02-01-2020